We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Richard
Oram
r.oram@exeter.ac.uk
Mrs
Michelle
Hudson
m.hudson@exeter.ac.uk
Michelle
Hudson
michelle.hudson@nihr.ac.uk
Diabetes mellitus
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
A study to assess clinical phenotype, beta cell function, genetics, and autoantibodies in Extremely Early Type 1 Diabetes (EET1D) to better understand the aetiology and progression of beta cell destruction in Type 1 diabetes (T1D) occurring in the first year of life.
As a study of a very rare disease ( < 100 in UK) defined by genetics, it is adopted as a Musketeers' Memorandum Study.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Case-controlled study;
You can take part if:
You may not be able to take part if:
Study 1: • Aged > 70 years • No diagnosis of diabetes • Non-T1D, such as MODY, type 2 diabetes or diabetes related to pancreatic insufficiency or syndromic diabetes • Intercurrent illness at time of sampling for PBMCs (see below). Study 2: • Aged > 18 months • Clinical diagnosis of diabetes > 14 months • Inter-current illness at time of sampling for PBMCs or RNA (see below). For PBMC and RNA sampling: Exclusion for factors that may alter T cell function and RNAseq Review the following exclusion criteria carefully at time of appointment as some details may have changed since initial contact: • Recreational drug use (excluding cannabis use more than 1 week prior to blood sampling) - drug abuse may alter T cell function • Alcohol related illness (excessive alcohol consumption may alter T cell function) • Renal failure: Creatinine > 200 (as may alter T cell function) • Any other medical condition which, in the opinion of the investigator, would affect the safety of the subject's participation. Factors that if temporary would lead to rearrangement of study visit but if long duration, may lead to exclusion subject to the CI’s discretion: • Pregnant or lactating (as this may limit blood sampling and affect T cell function) • Any infectious illness within the last 2 weeks if it was a febrile illness, or within 2-3 days if it was non-febrile (as this may activate T cells non-specifically) • Taking steroids or other immunosuppressive medications (as these may alter T cell function) • Received any immunoglobulin treatments or blood products in the last 3 months (as these may alter T cell function).
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Richard
Oram
r.oram@exeter.ac.uk
Mrs
Michelle
Hudson
m.hudson@exeter.ac.uk
Michelle
Hudson
michelle.hudson@nihr.ac.uk
The study is sponsored by University of Exeter and funded by THE BRITISH DIABETIC ASSOCIATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 35336
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
